Table 1. Characteristics of the transplanted patients, ESRD patients and normal subjects in the study.
| Early graf function (n = 13) | Slow graft function (n = 12) | ||
| RECIPIENTS | |||
| Age, years | 53.8±14.1 | 56.1±12.1 | ns |
| Sex, (M/F) | 6/7 | 11/2 | |
| Cause of chronic kidney disease | Unknown, 3; Chronicpyelonephritis, 2; APKD, 2;Gn, 5; nephroangiosclerosis, 1. | Unknown, 1; Chronic pyelonephritis,3; Gn, 5; nephroangiosclerosis, 1;diabetic nephropathy, 2;hemolytic-uremic syndrome, 1. | |
| Prior treatment | |||
| Hemodialysis, No (%) | 11 (84) | 10 (77) | ns |
| Peritoneal dialysis, No (%) | 2 (15.3) | 3 (23) | ns |
| Time on dialysis (months) | 51.1±48.9 | 71.5±126 | ns |
| Retransplant, No (%) | 3 (23) | 3 (23) | ns |
| Panel reactive Antibody >20%, No (%) | 2 (15.3) | 1(7.7) | ns |
| ≥4 HLA mismatches, No (%) | 12 (100%) | 11 (84%) | ns |
| LD/DD | 0/13 | 1/12 | ns |
| Cold ischemia time, h | 14.5±5 | 14.1±5.5 | ns |
| Induction ID, No. (%) | |||
| Basiliximab | 13 (100) | 11 (84) | ns |
| Rituximab | 0 | 1 (7) | ns |
| No induction | 0 | 1 (7) | ns |
| Maintenance ID, No. (%) | |||
| Tacrolimus | 13 (100) | 12 (92) | ns |
| Mycophenolate mofetil | 11 (84) | 12 (92) | ns |
| Steroid | 13 (100) | 13 (100) | ns |
| Urine 24-h volume (ml) | |||
| Before transplantation | 577±701 | 700±730 | ns |
| day 1 post-transplant | 2875±2799 | 1110±989 | p = 0.02 |
| day 7 post-transplant | 3706±1098 | 3881±2025 | ns |
| GFR | ns | ||
| day 1 post-transplant | 14.2±6.5 | 12.8±4.3 | ns |
| day 7 post-transplant | 45.2±23 | 14.3±5.4 | p = 0.0001 |
| DONORS | |||
| Age, years | 60.9±20.5 | 67.3±11 | ns |
| ECD, No (%) | 11 (84%) | 11 (84%) | ns |
| GFR (ml/min) | 98.8±49 | 84.3±17 | ns |
| Hypertension, No (%) | 8 (61.5) | 9 (69.2) | ns |
| Diabetes, No (%) | 3 (23) | 1 (7.7) | |
| Histological score | |||
| Glomerular sclerosis | 1.2±0.4 | 0.9±0.3 | p = 0.04 |
| Tubular atrophy | 0.2±0.4 | 0.1±0.3 | ns |
| Interstitial fibrosis | 0.5±0.5 | 0.3±0.5 | ns |
| Arterial and arteriolar narrowing | 1.2±0.4 | 0.9±0.5 | ns |
| Final score | 3±1 | 2.2±0.9 | p = 0.04 |
| ESRD patients (n = 5) | |||
| Age, yrs | 54.4±17,6 | ||
| Sex, (M/F) | 1/4 | ||
| Cause of chronic kidney disease | APKD, 2; Unknown, 1;nephroangiosclerosis, 1;Cisplatin-inducednephropathy, 1 | ||
| Urine 24-hours volume (ml) | 1780±705 | ||
| CONTROL SUBJECTS (n = 20) | |||
| Age, yrs | 51.8±17.1 | ||
| Sex, (M/F) | 11/9 |
ECD: expanded criteria donors according to Crystal City Meeting criteria [35]. GFR: glomerular filtration rate. Histological score: performed on pretransplant biopsies according to a semiquantitative method [25]. APKD: adult polycystic kidney disease; Gn: glomerulonephritis; LD: living donor; DD: deceased donor. ID: immunosuppressive therapy. ESRD: end-stage kidney disease. Continuous variables are express as mean ± SD.